Agreement worth up to $495 million is part of a growing number of Chinese deals with global pharma giants as the country ...

Pfizer said it would acquire weight loss biotech Metsera in a deal valued at up to $7.3 billion, including future payments, as it scrambles to win a slice in the booming obesity drug market. The move ...

Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company’s up to $10 billion acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer’s strategy for clinical ...

Amid Novo Nordisk and Pfizer’s whiplash contest for obesity biotech Metsera, Novo’s CEO has, quite literally, told his company's rival to put its money where its mouth is. “Novo Nordisk and Pfizer ...

Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the ...

Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the PD-1 VEGF bispecific PF-4404 clinical development strategy. Today's call is being recorded. At this time, I would like to turn the ...

Pfizer appears cheap with a near 7% yield, but capital allocation constraints undermine its investment case. Nearly all of PFE's free cash flow is consumed by dividends, leaving little for buybacks, ...